Daily Stock Analysis, ACST, Acasti Pharma Inc, priceseries

Acasti Pharma Inc. Daily Stock Analysis
Stock Information
Open
0.81
Close
0.72
High
0.81
Low
0.72
Previous Close
0.83
Daily Price Gain
-0.11
YTD High
1.30
YTD High Date
Jan 24, 2018
YTD Low
0.60
YTD Low Date
May 8, 2018
YTD Price Change
-0.27
YTD Gain
-27.24%
52 Week High
3.36
52 Week High Date
Nov 20, 2017
52 Week Low
0.60
52 Week Low Date
May 8, 2018
52 Week Price Change
-0.54
52 Week Gain
-42.83%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 23. 2017
1.45
Jan 24. 2017
1.52
1 Trading Days
5.17%
Link
LONG
Feb 17. 2017
1.33
Feb 21. 2017
1.41
1 Trading Days
5.64%
Link
Company Information
Stock Symbol
ACST
Exchange
NasdaqCM
Company URL
http://www.acastipharma.com
Company Phone
(450) 687-2262
CEO
Janelle D'Alvise
Headquarters
Quebec
Business Address
545 PROMENADE DU CENTROPOLIS, SUITE 100, LAVAL, CANADA H7T 0A3
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001444192
About

Acasti Pharma, Inc. engages in the research, development, and commercialization of krill oil-based forms of omega-3 phospholipid therapies. It seeks to treat certain cardiometabolic disorders such as abnormalities in blood lipids, also known as dyslipidemia. It sproduct candidate, CaPre, is being developed to treat severe hypertriglyceridemia. The company was founded by Henri Harland on February 1, 2002 and is headquartered in Laval, Canada.

Description

Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of therapies for the treatment of various cardiometabolic disorders primarily abnormalities in blood lipids. The company offers Onemia, a medical food product for the dietary management of omega-3 phospholipids deficiency, and related abnormal lipid profiles and cardiometabolic disorders. It also develops CaPre, a prescription drug candidate for the prevention and treatment of cardiometabolic disorders, such as hypertriglyceridemia. The company was incorporated in 2002 and is headquartered in Laval, Canada.